FDA sends warning letters to five online peptide sellers in one day
Letters dated August 24, 2026 name NuScience Peptides, Royal Peptides, Peptide Partners, Peak Performance Peptides, and TXP Innovations. FDA says 'research use only' labels did not change its reading of intended use.
Published October 3, 2026 · Twenty Residues editorial
What the record establishes
- All five letters are dated August 24, 2026 and allege the firms marketed unapproved new drugs and misbranded drugs under the Federal Food, Drug, and Cosmetic Act.
- The Royal Peptides letter names tirzepatide, semaglutide, retatrutide, SS-31 (elamipretide), PT-141, tesamorelin, and BIMORELIN.
- FDA's stated reasoning: despite 'for research use only' and 'not for human or animal consumption' labeling, website evidence established the products were intended as drugs for human use. It cites the sale of bacteriostatic water alongside a 'peptide guide' and 'peptide calculator.'
- Each firm was given 15 business days to respond with corrective steps.
What it does not establish
- A warning letter is not a court finding, a seizure, or a shutdown order. It is FDA's allegation and a demand for a response.
- The letters do not test or characterize the products. They say nothing about purity, identity, or contamination.
- Five letters on one day is a visible signal, but the letters themselves do not announce a policy change or a broader sweep.
What would change this
The firms' responses, a follow-up FDA action (seizure, injunction, consent decree), or a court ruling on whether the 'intended use' reading holds would each move this story.
The open question
FDA's position is that a 'research use only' label is irrelevant if the surrounding context implies human use. If that reading stands, is there any way to sell a research peptide online that FDA would accept?
We don't answer this one. Take it to wherever you argue about peptides, and send us the strongest case from either side.
Propose a question by emailor on the public record
Sources
- [1]Royal Peptides LLC — Warning Letter 734884 (FDA, 2026-08-24)
primaryFDA warning letter
- [2]NuScience Peptides LLC — Warning Letter 733652 (FDA, 2026-08-24)
primaryFDA warning letter
- [3]McDermott Will & Emery — Federal regulators and state boards crack down on RUO peptides
secondaryLaw-firm analysis
Related
FDA widens GLP-1 import alert; adds orforglipron to the Green List
The September 21 revision of Import Alert 66-80 broadens detention-without-examination to more peptide product codes and names which foreign API makers have cleared FDA's bar.
1 primary record · 0 secondary
Lilly files six lawsuits over retatrutide sold before approval
On August 12, 2026 Eli Lilly sued a med spa, a compounding pharmacy, and four online peptide sellers in California and Texas federal courts, and said it has referred more than 200 parties to regulators.
1 primary record · 1 secondary